# Obalon Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/obalon-therapeutics

- Industry: Medical Devices & Equipment
- Headquarters: Carlsbad, US
- Website: www.obalon.com
- Total disclosed funding: $50M
- Latest round: Series D (Jan 14, 2015)
- Investors on record: 11

## About

Obalon Therapeutics, Inc. is a medical device company focused on innovative solutions for weight management, notably through its FDA-approved Obalon Balloon System designed for individuals with obesity.Obalon Therapeutics, Inc. specializes in non-surgical weight-loss solutions, primarily through the Obalon Balloon System. Founded in 2008 and headquartered in Carlsbad, California, the company has undergone significant funding rounds, including a PIPE round raising USD 10.00 mn, with backing from Domain Associates and InterWest Partners. The company raised USD 75 mn in its IPO on October 5, 2016, selling 5 million shares at USD 15 per share. The founder's history includes previous ventures, contributing to the expertise driving Obalon's offerings.Obalon Therapeutics, Inc. offers the Obalon Balloon System, an FDA-approved swallowable, gas-filled balloon for adults with a BMI of 30 to 40 kg/m², used in conjunction with a structured diet and exercise plan. Additionally, the ReShape Gastric Vest is part of their product range, targeting similar demographics. Both solutions primarily cater to the North American market, providing less invasive alternatives to traditional bariatric surgery.In the most recent fiscal year, 2024, Obalon Therapeutics generated revenue of USD 8.01 mn with an EBITDA of USD -7.71 mn. The revenue primarily originates from direct sales to healthcare providers and patients, facilitated through distribution partnerships with specialized weight-loss management facilities.Obalon Therapeutics plans to enhance its product portfolio with additional weight-loss solutions designed for diverse demographics. The company aims to expand its market presence into international regions, specifically targeting Europe and Asia by 2025. Recent funding will be utilized to support research, development, and marketing initiatives for new product launches and to strengthen distribution channels as it seeks to build upon its existing customer base.

## Funding rounds

- Series D, Jan 14, 2015, $4.1M — Domain Associates, InterWest Partners, Okapi Venture Capital, Shinhan Venture Investment, Striker Partners, Axon Ventures, Bader Sultan & Bros. Co. W.L.L., Mirae Asset Venture Investment
- Series D, Aug 28, 2014, $16M — Adams Capital Management, Domain Associates, Okapi Venture Capital, Citigroup
- Series C, Dec 19, 2012, $5M — Domain Associates, InterWest Partners, Okapi Venture Capital
- Series C, May 17, 2012, $17M — Domain Associates, InterWest Partners, Okapi Venture Capital
- Series B, May 9, 2011, $3.5M — Okapi Venture Capital
- Series B, Dec 23, 2009, $1M — Okapi Venture Capital
- Series A, Apr 27, 2008, $4M — Domain Associates, Okapi Venture Capital, Phagia Technology, Inc.

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series C, Series D
- Okapi Venture Capital (https://capitalatlas.ai/funds/okapi-venture-capital) — Series A, Series B, Series C, Series D
- Phagia Technology, Inc. — Series A
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series C, Series D
- Adams Capital Management (https://capitalatlas.ai/funds/adams-capital-management) — Series D
- Citigroup — Series D
- Shinhan Venture Investment (https://capitalatlas.ai/funds/shinhan-venture-investment) — Series D
- Striker Partners (https://capitalatlas.ai/funds/striker-partners) — Series D
- Axon Ventures — Series D
- Bader Sultan & Bros. Co. W.L.L. — Series D
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series D